Jessica Flynn, MS

Research Biostatistician
Jessica Flynn, BS


Columbia University

Current Research Interest

Jessica’s current research interests involve working to develop new clinical trial endpoints. She is on the Volumetric CT for Precision Analysis of Clinical Trials (Vol-PACT) project team alongside Mithat Gonen, Chaya Moskowitz, Mike Curry and collaborators from several other institutions, all of whom are working towards this goal. Jessica also frequently collaborates with the bone marrow transplant service and works on many leukemia and lymphoma studies. Specifically, she works on projects related to chimeric antigen receptor (CAR) T cell therapy and will be involved in the analysis of future trials in this field. Additionally, she is involved the department’s Bridge to Biostats committee with the mission to conduct biostatistics outreach activities for underrepresented groups in the field. Jessica also runs Open Study Group, a bi-monthly meeting for the Master’s statisticians where they can share new statistical concepts and coding advancements they have learned.


  1. Flynn JR, Bartlett EK, Lichtman SM, Panageas KS. Employing competing risks analysis in an aging population where many patients die from other causes. J Geriatr Oncol. 2021 Sep 11;. doi: 10.1016/j.jgo.2021.09.002. [Epub ahead of print] PubMed PMID: 34521610.
  2. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7. PubMed PMID: 29880584; PubMed Central PMCID: PMC6385599.
  3. Wudhikarn K, Flynn JR, Rivière I, Gönen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park JH. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021 Aug 19;138(7):531-543. doi: 10.1182/blood.2020009515. PubMed PMID: 33851211; PubMed Central PMCID: PMC8377478.
  4. Wudhikarn K, Palomba ML, Pennisi M, Garcia-Recio M, Flynn JR, Devlin SM, Afuye A, Silverberg ML, Maloy MA, Shah GL, Scordo M, Dahi PB, Sauter CS, Batlevi CL, Santomasso BD, Mead E, Seo SK, Perales MA. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020 Aug 5;10(8):79. doi: 10.1038/s41408-020-00346-7. PubMed PMID: 32759935; PubMed Central PMCID: PMC7405315.
  5. Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, Coit DG, Ariyan CE. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020 Jan 1;126(1):76-85. doi: 10.1002/cncr.32506. Epub 2019 Oct 4. PubMed PMID: 31584709; PubMed Central PMCID: PMC6906249.